27 November 2016 : Laboratory Research
Inhibition of Angiotensin-II Production Increases Susceptibility to Acute Ischemia/Reperfusion Arrhythmia
Eylem TaskinABCDEF, Kadir Ali TuncerCDEG, Celal GuvenCDEF, Salih Tunc KayaCEF, Nurcan DursunABFGDOI: 10.12659/MSM.896350
Med Sci Monit 2016; 22:4587-4595
Abstract
BACKGROUND: Myocardial ischemia and reperfusion lead to impairment of electrolyte balance and, eventually, lethal arrhythmias. The aim of this study was to investigate the effects of pharmacological inhibition of angiotensin-II (Ang-II) production on heart tissue with ischemia-reperfusion damage, arrhythmia, and oxidative stress.
MATERIAL AND METHODS: Rats were divided into 4 groups: only ischemia/reperfusion (MI/R), captopril (CAP), aliskiren (AL), and CAP+AL. The drugs were given by gavage 30 min before anesthesia. Blood pressure and electrocardiography (ECG) were recorded during MI/R procedures. The heart tissue and plasma was kept so as to evaluate the total oxidant (TOS), antioxidant status (TAS), and creatine kinase-MB (CK-MB).
RESULTS: Creatine kinase-MB was not different among the groups. Although TAS was not affected by inhibition of Ang-II production, TOS was significantly lower in the CAP and/or AL groups than in the MI/R group. Furthermore, oxidative stress index was significantly attenuated in the CAP and/or AL groups. Captopril significantly increased the duration of VT during ischemia; however, it did not have any effect on the incidence of arrhythmias. During reperfusion periods, aliskiren and its combinations with captopril significantly reduced the incidence of other types of arrhythmias. Captopril alone had no effect on the incidence of arrhythmias, but significantly increased arrhythmias score and durations of arrhythmias during reperfusion. MAP and heart rate did not show changes in any groups during ischemic and reperfusion periods.
CONCLUSIONS: Angiotensin-II production appears to be associated with elevated levels of reactive oxygen species, but Ang-II inhibitions increases arrhythmia, mainly by initiating ventricular ectopic beats.
Keywords: Angiotensin-Converting Enzyme Inhibitors - pharmacology, Angiotensin II - metabolism, Amides - pharmacology, Antihypertensive Agents - pharmacology, Arrhythmias, Cardiac - physiopathology, Blood Pressure - drug effects, Captopril - pharmacology, Creatine Kinase, MB Form - metabolism, Fumarates - pharmacology, Heart - physiopathology, Heart Rate - drug effects, Myocardial Reperfusion Injury - physiopathology, Oxidative Stress - drug effects
Editorial
01 February 2025 : Editorial
Editorial: Current Approaches to Screening for Lung Cancer in Smokers and Non-SmokersDOI: 10.12659/MSM.948255
Med Sci Monit 2025; 31:e948255
In Press
Clinical Research
Evaluation of Knowledge, Attitudes, and Practices Toward Thyroid Nodules in 456 Patients with Thyroid NodulesMed Sci Monit In Press; DOI: 10.12659/MSM.945732
Review article
Comparative Efficacy of 3D-Printed Insoles in Managing Common Foot Conditions: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.947252
Clinical Research
Correlation Descriptive Study on Nurses' Professional Values and Job Satisfaction and the Ethical Climate o...Med Sci Monit In Press; DOI: 10.12659/MSM.945639
Clinical Research
Pre- and Post-Surgical MRI Analysis of Levator Ani in Pelvic Organ Prolapse Patients: A Single-Center StudyMed Sci Monit In Press; DOI: 10.12659/MSM.945993
Most Viewed Current Articles
17 Jan 2024 : Review article 6,967,723
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 701,731
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 25,246
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 19,861
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912